Literature DB >> 35001307

Analysis of the Frequency of 10 Polymorphic Markers of CDKN2A and RB1 Genes in Russian Populations.

M V Olkova1,2, O P Balanovsky3,4,5.   

Abstract

The study of population frequencies of rare clinically significant alleles is a prerequisite of the development of personalized medicine. We performed genotyping of 1785 DNA samples from representatives of Russian populations according to 10 benign polymorphic markers of two genes involved in oncogenesis: 3 variants of the CDKN2A gene (rs3731249, rs116150891, and rs6413464) and 7 markers of the RB1 gene (rs149800437, rs147754935, rs183898408, rs146897002, rs4151539, rs187912365, and rs144668210). Genotyping was performed using the Illumina biochip test system. The sample covered 28 populations of the Russian Federation and neighboring countries, which were later combined into 3 groups (Asian, European, and Caucasian). The information from the ALFA (NCBI) project was used as reference for the frequencies of these polymorphisms in the Asian and European populations. It was shown that rare alleles in 8 of 10 studied polymorphic markers are presented in Russian populations of European and Caucasian origin with frequencies that are tens and hundreds of times higher than the available data for Western European populations, and in Russian Asian populations, alternative alleles of 5 markers absent in the Asian population of the ALFA project were found. In the subpopulation of Astrakhan Tatars, exceptionally high frequencies of rare alleles were identified; this requires further study.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CDKN2A; RB1; genetic epidemiology; oncomarker; population frequency of the polymorphism

Mesh:

Substances:

Year:  2022        PMID: 35001307     DOI: 10.1007/s10517-022-05391-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.737


  7 in total

Review 1.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

2.  Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture.

Authors:  Markus Hassler; Shradha Singh; Wyatt W Yue; Maciej Luczynski; Rachid Lakbir; Francisco Sanchez-Sanchez; Thomas Bader; Laurence H Pearl; Sibylle Mittnacht
Journal:  Mol Cell       Date:  2007-11-09       Impact factor: 17.970

3.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Authors:  A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

Review 4.  RB1: a prototype tumor suppressor and an enigma.

Authors:  Nicholas J Dyson
Journal:  Genes Dev       Date:  2016-07-01       Impact factor: 11.361

Review 5.  Roles of pRB in the Regulation of Nucleosome and Chromatin Structures.

Authors:  Chiharu Uchida
Journal:  Biomed Res Int       Date:  2016-12-22       Impact factor: 3.411

6.  p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function.

Authors:  M Sen; N Akeno; A Reece; A L Miller; D S Simpson; K A Wikenheiser-Brokamp
Journal:  Oncogenesis       Date:  2017-04-17       Impact factor: 7.485

7.  Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes.

Authors:  Melissa S DeRycke; Shanaka Gunawardena; Jessica R Balcom; Angela M Pickart; Lindsey A Waltman; Amy J French; Shannon McDonnell; Shaun M Riska; Zachary C Fogarty; Melissa C Larson; Sumit Middha; Bruce W Eckloff; Yan W Asmann; Matthew J Ferber; Robert W Haile; Steven Gallinger; Mark Clendenning; Christophe Rosty; Aung K Win; Daniel D Buchanan; John L Hopper; Polly A Newcomb; Loic Le Marchand; Ellen L Goode; Noralane M Lindor; Stephen N Thibodeau
Journal:  Mol Genet Genomic Med       Date:  2017-07-23       Impact factor: 2.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.